NCT06545942 2026-04-17
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Active not recruiting
Clinical Trials
19 trialsNCT02893917 2026-04-13
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06785636 2026-04-07
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT03787680 2026-03-23
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT04748042 2026-03-06
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT03317392 2026-02-19
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03263650 2026-02-17
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT05498272 2026-01-23
NePtune
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT05252390 2025-11-06
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT03012321 2025-10-21
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Northwestern University
Phase 2 Active not recruiting
NCT05932862 2025-09-05
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
Phase 1 Recruiting
NCT04038502 2025-08-20
COBRA
VA Office of Research and Development
Phase 2 Recruiting
NCT07090369 2025-07-29
LumOnate
Peter MacCallum Cancer Centre, Australia
Phase 1 Not yet recruiting
NCT02769962 2025-07-28
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT03432897 2025-07-08
337
Brown University
Phase 2 Terminated
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed